| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Present address: Fusion Technologies, Inc., 1615 Plymouth St., Mountain View, CA 94043.
2
Present address: Collagen Corp., 2500 Faber Pl., Palo
Alto, CA 94303.
a Author for correspondence. Fax 415-903-9500; e-mail djenkins{at}metrabio com.
We have compared the analytical performance and biological variability of three commercially available bone resorption assays: Pyrilinks®-D, Osteomark®, and CrossLapsTM, for the measurement of urinary free deoxypyridinoline (Dpd), cross-linked N-telopeptides of type I collagen (NTx), and linear C-telopeptides of type I collagen (CTx), respectively. The intraassay and interassay CVs for precision of the Dpd and NTx assays were <10% for analyte concentrations greater than the second calibrator (i.e., 3 nmol/L Dpd or 30 nmol bone collagen equivalents/L NTx). The CTx assay demonstrated poor precision for analyte concentration lower than the third calibrator (i.e., 200 µg/L). The NTx assay exhibited nonlinear recovery for sample dilutions prepared in buffer; however, this nonlinear recovery could be corrected for sample dilutions made in urine at a low analyte concentration. Supplement recoveries of each of the three assays were within 100% ± 10% on average. All three analytes showed stability through five freeze–thaw cycles. The mean day-to-day variations were 16% for Dpd, and 23% for both NTx and CTx. Similar diurnal rhythm was observed for all three assays on average, with the peak in the early morning and the nadir in the afternoon. Mean amplitude of the diurnal variation was 37% for Dpd and NTx, and 57% for CTx. Variations within the reference intervals for a healthy premenopausal population were 28% for Dpd, 57% for NTx, and 56% for CTx. Pyrilinks-D has demonstrated analytical precision and accuracy equal or superior to Osteomark and CrossLaps in all areas. Dpd exhibits the least biological variability day-to-day, within individuals across the diurnal cycle, and within a healthy premenopausal population.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. Mueller, R. Dittrich, H. Binder, W. Kuehnel, T. Maltaris, I. Hoffmann, and M. W Beckmann High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone Eur. J. Endocrinol., July 1, 2005; 153(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Taxel, P. M. Fall, K. M. Prestwood, L. Dulipsingh, D. Dauser, C. Ohannessian, and L. G. Raisz Changes in Urinary Excretion of Helical Peptide during Therapy for Osteoporosis in Older Adults Clin. Chem., April 1, 2004; 50(4): 747 - 750. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Amory, N. B. Watts, K. A. Easley, P. R. Sutton, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, and J. L. Tenover Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 503 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. D. Wolthers, C. Heuck, and L. Heickendorff Diurnal Variations in Serum and Urine Markers of Type I and Type III Collagen Turnover in Children Clin. Chem., September 1, 2001; 47(9): 1721 - 1722. [Full Text] [PDF]
|
|
|
|
|
|
M. Kleerekoper Biochemical Markers of Bone Turnover: Why Theory, Research, and Clinical Practice Are Still in Conflict Clin. Chem., August 1, 2001; 47(8): 1347 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Seibel, M. Lang, and W.-J. Geilenkeuser Interlaboratory Variation of Biochemical Markers of Bone Turnover Clin. Chem., August 1, 2001; 47(8): 1443 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Heuck, L. Heickendorff, and O. D Wolthers A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide Arch. Dis. Child., October 1, 2000; 83(4): 334 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wichers, E. Schmidt, F. Bidlingmaier, and D. Klingmuller Diurnal Rhythm of CrossLaps in Human Serum Clin. Chem., October 1, 1999; 45(10): 1858 - 1860. [Full Text] [PDF]
|
|
|
|
|
|
A. Rubinacci, R. Melzi, M. Zampino, A. Soldarini, and I. Villa Total and Free Deoxypyridinoline after Acute Osteoclast Activity Inhibition Clin. Chem., September 1, 1999; 45(9): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Orwoll, N. H. Bell, M. S. Nanes, K. A. Flessland, M. B. Pettinger, N. J. S. Mallinak, and D. F. Cain Collagen N-Telopeptide Excretion in Men: The Effects of Age and Intrasubject Variability J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3930 - 3935. [Abstract] [Full Text]
|
|
|
|
|
|
E. E. Fradinger, G. Rodriguez, C. Bogado, and J. R. Zanchetta Effect of Antiresorptive Therapy on Day-to-Day Variation of Urinary Free Deoxypyridinoline Excretion Clin. Chem., October 1, 1998; 44(10): 2224 - 2225. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Arnaud Biochemical Markers of Bone Turnover for Predicting BMD in Early Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1044a - 1045. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
